Viatris, Cipla and Aurobindo sign up to make generics of GSK’s long-acting HIV PrEP drug

Title: Viatris, Cipla, and Aurobindo to Produce Generics of GSK’s Long-Acting HIV PrEP Drug


The fight against HIV/AIDS has taken a significant step forward as pharmaceutical companies Viatris, Cipla, and Aurobindo have signed agreements to manufacture generic versions of GlaxoSmithKline’s (GSK) long-acting HIV pre-exposure prophylaxis (PrEP) drug. This development is a crucial milestone in improving access to affordable HIV prevention options and expanding global efforts to combat HIV transmission. In this blog, we delve into the key points surrounding the production of generics for GSK’s long-acting HIV PrEP drug.

Key Points:

  1. Importance of HIV Pre-Exposure Prophylaxis (PrEP) Drugs:

PrEP drugs play a crucial role in preventing the transmission of HIV. They are taken by individuals who are at high risk of acquiring HIV infection to reduce their chances of contracting the virus. GSK’s long-acting PrEP drug is particularly significant as it offers extended protection with less frequent dosing, increasing convenience and adherence for patients.

  1. Expansion of Access with Generic Drug Production:

The agreements between GSK and pharmaceutical companies Viatris, Cipla, and Aurobindo to manufacture generic versions of the long-acting HIV PrEP drug will significantly expand access to this critical medication. Generic drugs are more affordable than brand-name drugs, making them accessible to a larger population, particularly in low- and middle-income countries where HIV prevalence is high. This move can potentially lower barriers to HIV prevention and contribute to global efforts to eliminate HIV transmission.

  1. Role of Pharmaceutical Companies in Addressing Global Health Challenges:

The involvement of pharmaceutical companies such as Viatris, Cipla, and Aurobindo in producing generic versions of GSK’s long-acting PrEP drug demonstrates their commitment to addressing global health challenges. By leveraging their expertise and manufacturing capabilities, these companies can contribute to increasing the supply of affordable and high-quality HIV prevention options. This collaboration between industry leaders will strengthen the global response to HIV/AIDS and improve healthcare equity.

  1. Impact on Public Health:

The production of generic versions of GSK’s long-acting HIV PrEP drug will have a significant impact on public health. Making the drug more accessible will lead to increased uptake of HIV prevention strategies, reduce the number of new infections, and ultimately save lives. Lower-cost PrEP options can also alleviate the burden on healthcare systems and enable governments to allocate resources more effectively for comprehensive HIV/AIDS prevention programs.

  1. Advancing Global Efforts to End HIV Transmission:

Expanding access to effective HIV prevention tools, such as GSK’s long-acting PrEP drug, is vital to achieving the global goal of ending HIV transmission. By partnering with generic manufacturers, GSK is enabling the production of more affordable options and contributing to the broader global health agenda. These efforts align with the United Nations Sustainable Development Goals, specifically Goal 3 of ensuring good health and well-being for all.


The decision by pharmaceutical companies Viatris, Cipla, and Aurobindo to manufacture generic versions of GSK’s long-acting HIV PrEP drug marks a significant milestone in the fight against HIV/AIDS. Increasing access to affordable and effective prevention options is crucial in reducing new infections and advancing global efforts to end the transmission of HIV. The collaboration between industry leaders demonstrates the commitment of pharmaceutical companies to address global health challenges and improve healthcare equity. This development brings hope for a future where HIV transmission is effectively controlled, and individuals at risk have access to essential prevention strategies.